Thursday, August 13, 2015

Continued Effectiveness of Hormone Lite Called Into Question??!!

The following exchange of emails lays the groundwork for future personal "adventures" and new journal entries:
A. Recent Patient Portal Email to Dr. Myers
Over the past several months I have kept my Patient Portal inquiries to an absolute minimum. I intend to continue to do so. Currently, however, I feel compelled to call the following trends in my PSAs to your attention.
Over the past nine months my PSAs more than doubled, I. e., from .077 in December 2014  to  my current (August) reading of .18. This rise in PSAs is preceded by a drop from .365 in March of 2014 to .096 in November of 2014. Is this reversal of trends cause for concern in your professional judgment?

B. Dr. Myers Responds
WE DISCUSSED EXTENSIVELY THE OPTIONS VIA THIS PORTAL AND YOU WERE UNCOMFORTABLE WITH PROCEEDING. WE AGREED WE WOULD REVIEW THEM AT YOUR CLINIC VISIT AND MAKE A FINAL DECISION.

C. My Response to Dr. Myers
I am a major fan of the Patient Portal. It offers patients an opportunity to consult with you directly as issues arise. I have used this option often and much appreciate the prompt professional assistance provided by you and various members  of your staff.. I am equally appreciative of how effective Hormone Lite has been for me over the past two years solely due to your medical care and expertise. It is doubtful that I could have fared any better under the care of any other clinician anywhere.
If we have reached a point that my current protocol needs to be modified or replaced, I am prepared to discuss my options in any forum you deem appropriate. Our next regularly scheduled appointment is set for 11:30 A.M. on October 28,2015.

Addendum
 Positivity Produces Reciprocity
Dr. Myers responded to the above heartfelt statement with a more welcome, more compassionate message as shown below:
" I think we should move to daily bicalutimide. If the PSA does not respond, then in October we can adjust. I sent the script to your pharmacy."
This protocol modification represents an increase from three to seven 50 MG tablets weekly.